Who are Standard dose zonisamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): zonisamide high dose group, Placebo zonisamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-dose-zonisamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Standard dose zonisamide — Competitive Intelligence Brief

Standard dose zonisamide (Standard dose zonisamide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide anticonvulsant. Area: Neurology.

marketed Sulfonamide anticonvulsant Voltage-gated sodium channels, T-type calcium channels, GABA signaling Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Standard dose zonisamide (Standard dose zonisamide) — Mario Negri Institute for Pharmacological Research. Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Standard dose zonisamide TARGET	Standard dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA signaling
zonisamide high dose group	zonisamide high dose group	Eisai Korea Inc.	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA enhancement
Placebo zonisamide	Placebo zonisamide	Rose Research Center, LLC	phase 3	Sulfonamide anticonvulsant	Voltage-sensitive sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide anticonvulsant class)

Eisai Korea Inc. · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Rose Research Center, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard dose zonisamide — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-zonisamide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab